MARTIN AND HARRIS LABORATORIES | LATEST SHARE PRICE & UPDATES

Buy

₹ 1045

Sell

₹ 1595

Highly Undervalued

Company Overview

As a part of Apeejay Stya & Svran Group, Martin and Harris Laboratories is a manufacturing arm of Walter Bushnell, India’s leading pharmaceutical company. Incorporated in 1996, Martin and Harris Laboratories Ltd has won awards in the category of “Best innovator in process and formulation development” and Pharma Excellence awards 2018” from Ministry of Health and family Welfare, Govt. of India. 

As on 31-March-2021, the total outstanding shares of the Martin & Harris Laboratories Ltd were 39,96,040 shares of face value of Rs 10 each. At Rs 1,100 share price, the total market cap of the company came to approx. Rs 440 crores and P/E of 2.5x (1100/442). 

The company declared the following dividends in the recent past:

FY 2021- Rs 2.20 per share

FY 2020- Rs 1.80 per share

FY 2019- Rs 2 per share

FY 2018- Rs 2 per share

Martin and Harris is the proud manufacturer of leading pharmaceutical brands like Drotin, Bilalife, Uriliser, Microgest, Ovagen, Urispas, Amclox and Venusmin etc.

Business Model

Martin and Harris Laboratories manufactures drugs and medicines for anti-bacterial medicines, Parkinson disease, vaginal infection, anti-spasmodic drugs, fertilization, progestin, vitamin medicines, anabolic steroids, hormonal medicines, ovulatory stimulant.

Martin and Harris Laboratories has 2 manufacturing plants located at Roorkee and Una, Himachal Pradesh.

Martin and Harris Laboratories has one wholly owned subsidiary: Delite Infrastructure Pvt Ltd, engaged in the business of stock investments and financial derivatives (F&O) segment. It consistently distributed dividends for its investors. The company paid dividend of ₹ 2.20 and ₹ 1.80 per share during FY21 and FY20 respectively.

Registered Office:

The registered office of the company is located at Village- Pachgaon, NH-8, Delhi-Jaipur Highway, District: Gurgaon, Haryana.

SymbolMartin & Harris Laboratories Ltd.
Face Value (₹):10
ISIN:INE03VV01015
Demat Status:NSDL
Lot Size:15 Shares

Board of Directors

NameDesignation Profile
Harnam Thakur SinghDirectorNA Final 1
Shanker Laad LaxmanDirectorNA Final 1
Ajay GroverDirectorNA Final 1
Gopal Krishna NigamDirectorNA Final 1

Key Business Highlights

  • Martin and Harris is among the fastest-growing pharma companies with 29% CAGR sales growth.
  • Debt-free company with a D/E ratio of 0.01 (FY2019-20). 
  • Attractive financials with 21% ROE and 28% ROCE (FY 2019-20) and Martin and Harris Share Price have increased from last year.
  • Currently trading at below book value.

Financial Highlights

Particulars2020-212019-202018-192017-18
Total Income (₹ Crores)335.62296.72289.90177.38
PAT (₹ Crores)176.8612.7372.4459.37
Diluted EPS (₹)442.631.85181.28148.57
Book Value per Share (₹)1115.14673.47646.72454.45
Equity (₹ Crores)445.61269.12258.42181.60

Financial Charts

Chart by Visualizer
Chart by Visualizer
Chart by Visualizer
Chart by Visualizer

Shareholding Pattern

Chart by Visualizer

Peer Comparison

NameMarket Cap (₹ Crores)Profitability MarginROCEROED/E ratioP/E ratioP/B RatioBook Value per Share (₹)
Sun Pharma2003560017%7%12%3.432.014.05206.22
Dr. Reddy’s803870010%8%11%16.4641.054.561060.09
Martin & Harris50053%39%40%0.022.821.121115.14

Media Updates

Martin & Harris Laboratories report robust results in FY21, PAT zooms 139 per cent to Rs 177 Cr.

Read more: https://www.aninews.in/news/business/business/martin-amp-harris-labs-reports-robust-results-in-fy21-pat-zooms-139-per-cent-to-rs-177-cr20220115150701/

  • Martin & Harris Laboratories limited (Manufacturing Arm of Walter Bushnell), has been bestowed with the prestigious “Pharma Excellence Awards-2018 by apex industry chamber ASSOCHAM.
  • Martin & Harris Laboratories limited has been presented this prestigious honor for “Best Innovation in Process & Formulation Development. The award was given by Dr. Promila Gupta, Director General of Health Services, Ministry of Health & Family Welfare, Govt of India.

Read more:

https://www.facebook.com/WBPharmaceutical/photos/a.201779456838350/625153361167622/?type=3

Frequently Asked Questions (FAQs) on Martin & Harris Unlisted Shares

The buying and selling of unlisted shares, and pre-IPO shares is fully legal and valid.

The procedure to buy the Martin & Harris Laboratories shares is fairly simple. Once you have settled on the price and quantity of the transaction, you would have to transfer the funds into the bank account of the seller. Once the funds are transferred and transaction details are shared with the seller, your demat account will be credited with the shares either on the same day of the fund transfer or before the end of the next working day.

In the secondary market, the transactions related to unlisted shares take place with the existing owners of the shares who are generally the employees or existing investors in the company. The company itself is not directly involved.

The Martin & Harris Laboratories shares will get credited either the same day or before the end of the next working day when you transfer the funds into our bank account.

The minimum lot size varies on the basis of market conditions and demand and supply factors. To know the current lot size for Martin and Harris, please visit the stock page on our website: www.delistedstocks.in/current-offerings/martin-and-harris-laboratories-ltd/ 

There are many factors which influence the pricing of unlisted shares. Apart from the supply and demand factors, the latest transactions happened on the same stock, last funding round of the company, and valuation level of companies of the similar size affect the pricing of the unlisted shares.

Before IPO, there is no restriction on sale and transfer of your Martin & Harris Laboratories shares. But once the shares are listed on the stock exchange, for retail investors, there is a minimum lock-in period 6 months after listing on the stock exchange.

Once the selling price and quantity of shares is agreed with us, we will provide you with an UTR (Unique Transaction Reference) number to transfer the shares. Once you have transferred the shares into our company’s demat account, funds are released into your bank account within 24 hours or before the end of the next working day of the transfer of the shares.

If your holding period is less than 2 years, then such income is treated as business income and liable to get taxed as per tax slab of the investor. If your holding period is more than 2 years, then your profits would be subject to long-term capital gains tax. The current short-term capital gain tax rate is 20% after indexation.

The trading in unlisted shares is governed by Securities & Contract (Regulation) Act, which comes under the preview of SEBI.  The SEBI regulations become applicable when the stocks of the company get listed on the stock exchange. There is a minimum lock-in period of 6 months for pre-IPO investors.

The major risk associated with investing in unlisted stocks is the liquidity risk. The possible exit route for investors is either to sell to another investor or wait till the company gets listed on the stock exchange.

Yes, NRI’s can also buy and sell Martin & Harris Laboratories shares just like domestic investors. But their investment is on a non-repatriable basis.

The core business of the company is manufacturing pharmaceutical and medicinal chemical products. Besides, the company is also engaged in the business of trading financial derivatives through its 100% owned subsidiary: Delite Infrastructure Pvt Ltd.

Leave Your Message

Copyright © 2021 Delisted Stocks | Powered By EGS
1